Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 6 Results

Title
Intervention Indication Therapeutic Area Year Actions
Selpercatinib for advanced thyroid cancer with RET alterations Selpercatinib (LOXO-292; LY3527723) Medullary thyroid cancer (MTC) , Thyroid cancer Head and Neck Cancer , Oncology 2019 View  |  Download
Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Selpercatinib for previously untreated advanced RET fusion-positive non-small cell lung cancer Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Selpercatinib for previously untreated advanced RET-fusion positive thyroid cancer Selpercatinib (LOXO-292; LY3527723) Thyroid cancer Oncology 2022 View  |  Download
Selpercatinib for previously untreated medullary thyroid cancer with RET mutation in patients ages 12 and older Selpercatinib (LOXO-292; LY3527723) Medullary thyroid cancer (MTC) Head and Neck Cancer 2022 View  |  Download
Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications